These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Nakamura R; La Rosa C; Longmate J; Drake J; Slape C; Zhou Q; Lampa MG; O'Donnell M; Cai JL; Farol L; Salhotra A; Snyder DS; Aldoss I; Forman SJ; Miller JS; Zaia JA; Diamond DJ Lancet Haematol; 2016 Feb; 3(2):e87-98. PubMed ID: 26853648 [TBL] [Abstract][Full Text] [Related]
12. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial. Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644 [TBL] [Abstract][Full Text] [Related]
13. Vaccines for cytomegalovirus. Bernstein DI Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618 [TBL] [Abstract][Full Text] [Related]
14. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
16. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ; Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870 [TBL] [Abstract][Full Text] [Related]
17. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees. Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646 [TBL] [Abstract][Full Text] [Related]
18. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Marshall BC; Adler SP Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736 [TBL] [Abstract][Full Text] [Related]
19. Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial. Aldoss I; La Rosa C; Baden LR; Longmate J; Ariza-Heredia EJ; Rida WN; Lingaraju CR; Zhou Q; Martinez J; Kaltcheva T; Dagis A; Hardwick N; Issa NC; Farol L; Nademanee A; Al Malki MM; Forman S; Nakamura R; Diamond DJ; Ann Intern Med; 2020 Mar; 172(5):306-316. PubMed ID: 32040960 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]